A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia

Mutants of the FLT3 receptor tyrosine kinase (RTK) with duplications in the juxtamembrane domain (FLT3-ITD) act as drivers of acute myeloid leukemia (AML). Potent tyrosine kinase inhibitors (TKi) of FLT3-ITD entered clinical trials and showed a promising, but transient success due to the occurrence...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2020-05, Vol.193, p.112232, Article 112232
Hauptverfasser: Sellmer, Andreas, Pilsl, Bernadette, Beyer, Mandy, Pongratz, Herwig, Wirth, Lukas, Elz, Sigurd, Dove, Stefan, Henninger, Sven Julian, Spiekermann, Karsten, Polzer, Harald, Klaeger, Susan, Kuster, Bernhard, Böhmer, Frank D., Fiebig, Heinz-Herbert, Krämer, Oliver H., Mahboobi, Siavosh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mutants of the FLT3 receptor tyrosine kinase (RTK) with duplications in the juxtamembrane domain (FLT3-ITD) act as drivers of acute myeloid leukemia (AML). Potent tyrosine kinase inhibitors (TKi) of FLT3-ITD entered clinical trials and showed a promising, but transient success due to the occurrence of secondary drug-resistant AML clones. A further caveat of drugs targeting FLT3-ITD is the co-targeting of other RTKs which are required for normal hematopoiesis. This is observed quite frequently. Therefore, novel drugs are necessary to treat AML effectively and safely. Recently bis(1H-indol-2-yl)methanones were found to inhibit FLT3 and PDGFR kinases. In order to optimize these agents we synthesized novel derivatives of these methanones with various substituents. Methanone 16 and its carbamate derivative 17b inhibit FLT3-ITD at least as potently as the TKi AC220 (quizartinib). Models indicate corresponding interactions of 16 and quizartinib with FLT3. The activity of 16 is accompanied by a high selectivity for FLT3-ITD. [Display omitted] •Mutants of the FLT3 receptor tyrosine kinase act as drivers of acute myeloid leukemia.•A series of novel aryl-methanone derivatives as inhibitors of FLT3 was prepared.•Models indicate closely corresponding interactions of these inhibitors and quizartinib.•The aryl-methanone derivatives show an improved activity towards FLT3 mutants.•The activity of is accompanied by a high specificity for FLT3-ITD.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2020.112232